Agile Therapeutics Received A Letter Notifying The Company That It Had Been Granted Until Feb. 16, 2024, To Regain Compliance With The Minimum Stockholders' Equity Requirement For Continued Listing On The Nasdaq Capital Market
Agile Therapeutics Received A Letter Notifying The Company That It Had Been Granted Until Feb. 16, 2024, To Regain Compliance With The Minimum Stockholders' Equity Requirement For Continued Listing On The Nasdaq Capital Market
Agile Therapeutics收到一封信,通知該公司已獲准在2024年2月16日之前恢復遵守繼續在納斯達克資本市場上市的最低股東權益要求
Agile Therapeutics Received A Letter Notifying The Company That It Had Been Granted Until Feb. 16, 2024, To Regain Compliance With The Minimum Stockholders' Equity Requirement For Continued Listing On The Nasdaq Capital Market
Agile Therapeutics收到一封信,通知該公司已獲准在2024年2月16日之前恢復遵守繼續在納斯達克資本市場上市的最低股東權益要求